Metropolis, Dr Lal PathLabs shares dip up to 3%

Diagnostic stocks including Metropolis Healthcare, Dr Lal PathLabs, Krsnaa Diagnostics, and Thyrocare Technologies came under pressure during Monday’s trade (June 23), falling up to 3% intraday as investor sentiment turned cautious after Amazon launched home diagnostic services, intensifying competition in India’s $15 billion diagnostics market. On Sunday, Amazon India announced the launch of Amazon Diagnostics — an at-home service that allows customers to book lab tests, schedule and track appointments, and access digital reports via the Amazon app — marking an expansion of its medical offerings beyond online pharmacy and teleconsultations.